Deep and Durable Response to Nivolumab and Temozolomide in Small-Cell Lung Cancer Associated With an Early Decrease in Myeloid-Derived Suppressor Cells

•Platinum-resistant small-cell lung cancer (SCLC) is characterized by low response rates and short survival.•This case demonstrates sustained response to nivolumab and temozolomide as part of a clinical trial in platinum-resistant SCLC.•Clinical response was accompanied by a decrease in immunosuppre...

Full description

Saved in:
Bibliographic Details
Published in:Clinical lung cancer 2021-07, Vol.22 (4), p.e487-e497
Main Authors: Owen, Dwight H., Benner, Brooke, Pilcher, Carly, Good, Logan, Savardekar, Himanshu, Norman, Ruthann, Ghattas, Christian, Shah, Manisha, Konda, Bhavana, Verschraegen, Claire F., Wesolowski, Robert, Behbehani, Gregory K., Carson, William E., Otterson, Gregory A.
Format: Article
Language:English
Subjects:
Aged
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Biomarker
Chemotherapy
Humans
Immune checkpoint inhibitor
Immunomodulation
Immunotherapy
Lung Neoplasms - drug therapy
Lung Neoplasms - pathology
Male
Myeloid-Derived Suppressor Cells - metabolism
Nivolumab - administration & dosage
Small Cell Lung Carcinoma - drug therapy
Small Cell Lung Carcinoma - pathology
Temozolomide - administration & dosage
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Platinum-resistant small-cell lung cancer (SCLC) is characterized by low response rates and short survival.•This case demonstrates sustained response to nivolumab and temozolomide as part of a clinical trial in platinum-resistant SCLC.•Clinical response was accompanied by a decrease in immunosuppressive myeloid-derived suppressor cells, which may be an early biomarker of response to treatment.
ISSN:1525-7304
1938-0690
DOI:10.1016/j.cllc.2020.10.018